SEARCH

SEARCH BY CITATION

References

  • 1
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000; 32: 9196.
  • 2
    Alberti A, Chemello L, Benvegnáu L. Natural history of hepatitis C. J Hepatol 1999; 31(Suppl 1): 1724.
  • 3
    Forton DM, Taylor-Robinson SD, Thomas HC. Reduced quality of life in hepatitis C—is it all in the head? J Hepatol 2002; 36: 435438.
  • 4
    Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002; 32: 110.
  • 5
    Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. HEPATOLOGY 1999; 29: 277279.
  • 6
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334343.
  • 7
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. HEPATOLOGY 1998; 27: 209212.
  • 8
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. HEPATOLOGY 1999; 29: 264270.
  • 9
    Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed-Pee N, Walsh J, Klein S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001; 96: 170178.
    Direct Link:
  • 10
    Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok AS. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 27372744.
    Direct Link:
  • 11
    Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. HEPATOLOGY 1999; 30: 12991301.
  • 12
    Bretteville-Jensen A, Ødegård E. Injecting drug users in Norway. Report from The National Institute for Alchol and Drug Research 1999; 4: 8283.
  • 13
    Ware JRJE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A Users Manual. Nosto, MA: The Health Institute, New England Medical Center, 1994.
  • 14
    Jenkinson C. Evaluating the efficacy of medical treatment: possibilities and limitations. Soc Sci Med 1995; 41: 13951401.
  • 15
    McHorney CA, Ware JrJE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247263.
  • 16
    Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160164.
  • 17
    Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993; 306: 14401444.
  • 18
    McHorney CA, Ware JrJE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 4066.
  • 19
    Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrica 1951; 16: 297334.
  • 20
    Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998; 26: 250258.
  • 21
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997; 26: 747754.
  • 22
    Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31(Suppl 1): 8891.
  • 23
    McHutchison JG, Ware JrJE, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140147.
  • 24
    Ware JrJE, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. HEPATOLOGY 1999; 30: 550555.
  • 25
    Kleinman L, Barker CM, Revicki DA, Green J, Bernstein D. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704708.
  • 26
    Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. Soc Sci Med 1999; 49: 15711598.
  • 27
    Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996; 91: 3945.
  • 28
    Ware JrJE, Snow K K, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1997.
  • 29
    Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill, 1994.
  • 30
    Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996; 41: 7580.
  • 31
    Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 3955.